Myriad Genetics Shares Outstanding 2006-2021 | MYGN

Myriad Genetics shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Myriad Genetics Annual Shares Outstanding
(Millions of Shares)
2020 74
2019 76
2018 72
2017 69
2016 73
2015 75
2014 78
2013 83
2012 86
2011 92
2010 99
2009 99
2008 93
2007 86
2006 73
2005 61
Myriad Genetics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 77
2021-03-31 76
2020-12-31
2020-09-30 75
2020-06-30 75
2020-03-31 75
2019-12-31 74
2019-09-30 74
2019-06-30
2019-03-31 75
2018-12-31 77
2018-09-30 73
2018-06-30
2018-03-31 72
2017-12-31 72
2017-09-30 70
2017-06-30
2017-03-31 68
2016-12-31 68
2016-09-30 69
2016-06-30
2016-03-31 74
2015-12-31 74
2015-09-30 72
2015-06-30
2015-03-31 74
2014-12-31 75
2014-09-30 76
2014-06-30
2014-03-31 76
2013-12-31 77
2013-09-30 82
2013-06-30
2013-03-31 82
2012-12-31 84
2012-09-30 84
2012-06-30
2012-03-31 86
2011-12-31 86
2011-09-30 87
2011-06-30
2011-03-31 90
2010-12-31 94
2010-09-30 95
2010-06-30
2010-03-31 100
2009-12-31 99
2009-09-30 99
2009-06-30
2009-03-31 100
2008-12-31 98
2008-09-30 97
2008-06-30
2008-03-31 89
2007-12-31 88
2007-09-30 87
2007-06-30
2007-03-31 83
2006-12-31 80
2006-09-30 79
2006-06-30
2006-03-31 78
2005-12-31 71
2005-09-30 62
2005-06-30
2005-03-31 61
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.600B $0.639B
Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering innovative products that transform patients' lives. These products include leading molecular diagnostic tests for hereditary cancer, urological cancer, lung cancer, autoimmune disorders and other diseases. Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Myriad's hereditary cancer genetic testing, which helps healthcare professionals better manage and tailor medical care. Myriad is expanding their reach and increasing their impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29